Format

Send to

Choose Destination
Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229.

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Author information

1
From the *Department of Medicine, George Washington University Medical Center, Rockville, MD; †Department of Internal Medicine/Diabetology, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany; ‡Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; §Thyroid Unit and Department of Medicine, Massachusetts General Hospital Harvard Medical School, Boston, MA; ║Park Nicollet Institute for Research and Education, International Diabetes Center, Minneapolis, MN; ¶Department of Medicine, Friedrich Alexander University of Erlangen, Erlangen, Germany; #Novo Nordisk, A/S, Bagsvaerd, Denmark; **Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX; and ††Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.

Abstract

OBJECTIVES:

This report from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial describes baseline lipase and amylase activity in type 2 diabetic subjects without acute pancreatitis symptoms before randomization to the glucagonlike peptide analog liraglutide or placebo.

METHODS:

The LEADER is an international randomized placebo-controlled trial evaluating the cardiovascular safety of liraglutide in 9340 type 2 diabetic patients at high cardiovascular risk. Fasting lipase and amylase activity was assessed at baseline, before receiving liraglutide or placebo, using a commercial assay (Roche) with upper limit of normal values of 63 U/L for lipase and 100 U/L for amylase.

RESULTS:

Either or both enzymes were above the upper limit of normal in 22.7% of subjects; 16.6% (n = 1540) had an elevated lipase level (including 1.2% >3-fold elevated), and 11.8% (n = 1094) had an elevated amylase level (including 0.2% >3-fold elevated). In multivariable regression models, severely reduced kidney function was associated with the largest effect on increasing activity of both. However, even among subjects with normal kidney function, 12.2% and 7.7% had elevated lipase and amylase levels.

CONCLUSIONS:

In this large study of type 2 diabetic patients, nearly 25% had elevated lipase or amylase levels without symptoms of acute pancreatitis. The clinician must take these data into account when evaluating abdominal symptoms in type 2 diabetic patients.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01179048.

PMID:
25275271
PMCID:
PMC4206347
DOI:
10.1097/MPA.0000000000000229
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center